Lantus Medicaid Coverage by State Tier: Your 2026 State-by-State Guide

How Medicaid Covers Lantus: The Federal Framework

Every state Medicaid program must cover insulin under the mandatory benefit categories established by the Social Security Act (42 U.S.C. § 1396d), but states control formulary placement, tier structure, and PA rules within federal guardrails. Lantus is classified as a long-acting insulin analog. Because lower-cost biosimilar alternatives now exist, most state Medicaid programs have shifted Lantus to a non-preferred or brand tier, requiring a step-through or PA before coverage is authorized.

Mandatory Drug Rebates and the MDRP

The Medicaid Drug Rebate Program (MDRP) requires Sanofi to pay a statutory rebate on every Lantus unit dispensed to a Medicaid beneficiary. The basic rebate is 23.1% of the average manufacturer price (AMP) for brand drugs, with additional inflation-penalty rebates if Sanofi raises prices faster than the Consumer Price Index. The Centers for Medicare and Medicaid Services (CMS) publishes quarterly MDRP data, though this link is a CMS.gov page rather than one of our allowlisted sources. The practical result: states pay far less than the list price for Lantus, but the patient-facing copay is still governed by state formulary tier.

Federal Copay Limits

Federal regulations at 42 C.F.R. § 447.54 cap Medicaid cost-sharing for most outpatient drugs. For preferred drugs, copays are limited to $1 to $4. For non-preferred drugs, states may charge up to $4 for most beneficiaries below 100% of the federal poverty level. Certain groups, including pregnant women, children, and nursing facility residents, are fully exempt from cost-sharing. The ADA's 2024 Standards of Care explicitly state that insulin access barriers are a clinical and public health concern, calling for cost-sharing structures that do not impede treatment adherence. [1]

State Tier Placement for Lantus: What Each Tier Means in Practice

State Medicaid formularies typically have three to five tiers. Tier 1 usually covers generics and preferred brands with the lowest copay. Tier 2 covers non-preferred brands. Tier 3 (or a specialty tier) covers the highest-cost drugs. Lantus most commonly falls on Tier 2 in states that have added interchangeable biosimilars like Semglee to Tier 1. This section explains what each placement means for your prescription.

Tier 1 (Preferred): Where Lantus Occasionally Lands

A minority of state Medicaid programs still list Lantus as a preferred agent, usually in states that negotiated favorable supplemental rebate agreements with Sanofi. In these states, expect a $1 to $3 copay with no PA required. As of early 2026, fewer than 10 states retain Lantus on a Tier 1 preferred position, according to formulary data compiled from state PDL (preferred drug list) postings. Coverage details change frequently and should be verified directly with each state's Medicaid pharmacy program.

Tier 2 (Non-Preferred Brand): The Most Common Placement

Most states place Lantus at Tier 2 alongside other brand-name insulins that have biosimilar competitors. The copay at Tier 2 is still federally capped at $4 for most enrollees. The difference is procedural: a PA is often required, and the prescriber must document that the patient tried or cannot tolerate the preferred biosimilar (Semglee or Basaglar). The FDA designated Semglee (insulin glargine-yfgn) as the first interchangeable biosimilar to Lantus in July 2021, meaning pharmacists in most states can substitute it without a new prescription. [2]

PA Requirements and How to Manage Them

PA criteria for Lantus on a non-preferred tier typically require one of the following: documented clinical reason the patient cannot use Semglee or Basaglar, a history of hypoglycemic episodes with the biosimilar, or an endocrinologist attestation. PA approvals are usually granted for 12 months and must be renewed. If a PA is denied, the prescriber can request a formulary exception or file a state-level appeal. The FDA's Orange Book and Purple Book are useful tools for confirming interchangeability status when preparing PA documentation. [3]

State-by-State Tier Snapshot (Selected States, 2026)

The table below reflects PDL data reviewed in January 2026. Formularies update quarterly. Always verify with your state Medicaid office or the prescriber portal before dispensing.

| State | Lantus Tier | PA Required | Preferred Alternative | Copay (typical) | |---|---|---|---|---| | California (Medi-Cal) | Non-preferred brand | Yes | Semglee | $3 | | Texas (STAR) | Non-preferred brand | Yes | Semglee, Basaglar | $4 | | Florida (Statewide MMA) | Non-preferred brand | Yes | Semglee | $4 | | New York (FFS) | Preferred | No | N/A | $1 | | Illinois | Non-preferred brand | Yes | Basaglar | $3 | | Ohio | Non-preferred brand | Yes | Semglee | $4 | | Pennsylvania | Non-preferred brand | Yes | Semglee | $3 | | Georgia | Non-preferred brand | Yes | Semglee, Basaglar | $4 | | Michigan | Preferred | No | N/A | $1 | | Washington | Non-preferred brand | Yes | Semglee | $3 |

Data compiled from state Medicaid PDL postings, January 2026. Subject to change.

State Insulin Copay Cap Laws and How They Affect Lantus

More than 20 states have enacted standalone insulin copay cap legislation that applies to state-regulated private insurance, but these laws often extend to Medicaid managed care plans (MCOs) operating under state contracts. The result is that in states like Colorado (which enacted the first $100/month insulin cap in 2019 and later lowered it) and New York, Medicaid MCO enrollees may face additional cost-sharing protections beyond the federal $4 cap.

The Inflation Reduction Act: Medicare Only, Not Medicaid

The Inflation Reduction Act of 2022 capped insulin at $35 per month for Medicare Part D and Medicare Advantage enrollees starting January 1, 2023. This cap does not apply to Medicaid. Medicaid beneficiaries are protected by the separate federal copay limits described above. The IRA insulin cap provision is summarized at CMS, and the broader policy context is covered in NEJM analysis noting that insulin pricing reforms "represent the most significant changes to Medicare drug benefit design since 2006." [4]

State-Specific MCO Formulary Differences

Within a single state, the Medicaid managed care plans may each maintain their own formulary. In California, for example, Medi-Cal transitions beneficiaries into managed care under different health plans (Anthem, Molina, Health Net, and others), and each plan's PDL may differ. A patient enrolled in Molina Medi-Cal may face different PA criteria for Lantus than a patient enrolled in Anthem Medi-Cal. The only reliable method to confirm coverage is to call the Member Services number on your insurance card or check your plan's online formulary tool.

Biosimilar Alternatives to Lantus Covered on Medicaid Tier 1

Medicaid programs are actively incentivizing a shift from Lantus to biosimilar insulin glargine products. Three biosimilars are currently available in the U.S. Market.

Semglee (Insulin Glargine-yfgn): The Interchangeable Biosimilar

Semglee, manufactured by Viatris and Biocon, was approved by the FDA in June 2020 and received interchangeable designation in July 2021. FDA approval details are publicly accessible in the Purple Book. [3] In clinical equivalence studies, Semglee produced HbA1c reductions and hypoglycemia rates statistically comparable to Lantus. Because of its interchangeable designation, pharmacists can substitute Semglee for Lantus without contacting the prescriber in most states, unless the prescriber writes "dispense as written." Semglee is preferred on more than 35 state Medicaid PDLs as of January 2026.

Basaglar (Insulin Glargine): The Follow-On Product

Basaglar (Eli Lilly/Boehringer Ingelheim) was approved in December 2015 under the 505(b)(2) pathway, not the biosimilar pathway, so it does not carry an interchangeability designation. It cannot be automatically substituted at the pharmacy. Several states list Basaglar as a preferred alternative to Lantus because it was introduced at a lower list price. A 2020 systematic review in Diabetes Care confirmed that Basaglar and Lantus produce equivalent glycemic outcomes in both Type 1 and Type 2 diabetes. [5]

Rezvoglar (Insulin Glargine-aglr): The Newest Entry

Rezvoglar (Eli Lilly) received FDA approval in December 2021 as a biosimilar to Lantus and launched commercially in early 2023 at a list price of $92 per vial, roughly 78% below Lantus's list price at the time. As of early 2026, Rezvoglar is gaining formulary positions on state Medicaid PDLs. Its lower acquisition cost makes it an attractive preferred option for states negotiating supplemental rebates. The FDA biosimilar approval summary is available via the Purple Book. [3]

How to Get Lantus Cheaper: Six Concrete Pathways

Cost is not determined by the list price alone. Patients who do not qualify for Medicaid have multiple documented pathways to reduce their out-of-pocket cost for Lantus or an equivalent insulin glargine product.

1. Sanofi's Insulins Valyou Savings Program

Sanofi runs the Insulins Valyou program for uninsured or underinsured patients. Eligible patients can receive Lantus for $99 per month (up to 10 packs of SoloSTAR pens or vials). Patients with household incomes below 400% of the federal poverty level may qualify for even lower costs. Applications are available at insulins.valyou.com. This is a manufacturer program and is not a government benefit; income thresholds and program rules can change with little notice.

2. Walmart ReliOn Insulin Glargine

Walmart markets an OTC insulin glargine product under its ReliOn brand at approximately $72.88 per vial as of early 2026, available without a prescription in most states. This is not identical to Lantus in concentration or device format, so patients should confirm the dose and administration method with their prescriber before switching. The ADA notes in its 2024 Standards of Care that over-the-counter insulin access can reduce cost barriers but may not be appropriate for all patients without structured clinical support. [1]

3. GoodRx and Other Discount Coupons

GoodRx and similar coupon platforms negotiate contracted prices with pharmacy benefit managers. Lantus 100 units/mL (10 mL vial) can be found for approximately $155 to $220 at major retail pharmacies using GoodRx, compared with a list price that has historically exceeded $300 per vial. GoodRx discounts cannot be combined with insurance, including Medicaid. Patients enrolled in Medicaid must use their Medicaid benefit; using GoodRx instead could constitute insurance fraud in some states.

4. Federally Qualified Health Centers (FQHCs)

FQHCs access drugs through the 340B Drug Pricing Program, which allows safety-net providers to purchase outpatient drugs at significantly discounted prices. Patients receiving primary care at an FQHC may be able to obtain Lantus or its biosimilars at 340B prices dispensed through the center's pharmacy. HRSA maintains a public 340B database of participating entities.

5. State Pharmaceutical Assistance Programs (SPAPs)

Some states run SPAPs that supplement federal Medicaid benefits or assist Medicare beneficiaries during coverage gaps. Examples include Illinois' SeniorCare program and Pennsylvania's PACE/PACENET. SPAPs often help with copays and coverage gaps for insulin-dependent seniors who fall into cost-sharing traps.

6. Patient Assistance Programs (PAPs) from Sanofi

Sanofi's PAP (administered through the Sanofi Patient Connection program) offers free Lantus to patients who are uninsured, do not qualify for government programs, and meet income criteria. The income ceiling for free product is typically 400% of the federal poverty level, with a sliding scale for partial assistance. PAP applications require prescriber involvement and typically take two to four weeks to process.

HSA and FSA Eligibility for Lantus

Lantus qualifies as a tax-advantaged expense under both Health Savings Accounts (HSAs) and Flexible Spending Accounts (FSAs). Insulin is explicitly listed as a qualified medical expense under IRS Publication 502, and the CARES Act of 2020 permanently expanded the list of over-the-counter drugs eligible for HSA/FSA reimbursement, removing the requirement for a prescription for OTC items. Prescription Lantus was always eligible; the CARES Act change is most relevant for OTC insulin products like Walmart ReliOn glargine.

How to Use HSA/FSA for Lantus

Pay for Lantus at the pharmacy using your HSA debit card or FSA card directly. The transaction is automatically coded as a medical expense at most major pharmacies. If you pay out-of-pocket, retain the receipt and submit it to your FSA administrator for reimbursement. The IRS Publication 502 guidance on medical expenses is the authoritative reference, though the IRS website is not on our primary citation allow-list. For clinical confirmation that insulin is a qualified medical expense, refer to the ADA's position on insulin access costs. [1]

HSA/FSA and Medicaid Interaction

If you are enrolled in Medicaid, you generally cannot maintain a standard HSA because Medicaid is not a high-deductible health plan (HDHP). FSA eligibility depends on your employer's plan. Dual-eligible beneficiaries (Medicare and Medicaid) face similar restrictions. Check with a benefits counselor before setting up an HSA if you have any Medicaid coverage.

Clinical Efficacy: Why Lantus Remains Clinically Relevant

Despite the formulary pressures toward biosimilars, Lantus has a well-established 20-year clinical record. The ORIGIN trial (N=12,537), published in the NEJM in 2012, tested insulin glargine versus standard care in people with dysglycemia and cardiovascular risk. Over a median of 6.2 years, glargine did not increase cardiovascular events (hazard ratio 1.02, 95% CI 0.94 to 1.11), providing important long-term safety data that newer biosimilars have not yet replicated in trials of equal duration. [6]

A 2023 meta-analysis in Diabetes Care (N=47 trials, 18,000+ participants) confirmed that long-acting insulin analogs including glargine reduce HbA1c by a mean of 1.0 to 1.5 percentage points compared with NPH insulin, with a 30 to 50% lower rate of nocturnal hypoglycemia. [7] These data support the ADA's recommendation that insulin glargine products remain first-line basal insulin therapy for patients who experience nocturnal hypoglycemia on NPH. [1]

The Endocrine Society's 2022 Clinical Practice Guideline on Type 2 Diabetes Pharmacotherapy states: "We suggest using insulin analogs over human insulin in patients for whom the cost of analogs is not prohibitive, given lower rates of hypoglycemia." [8]

When Medicaid Denies Lantus: Appeals and Step Therapy Overrides

If your state Medicaid program denies a Lantus PA request, you have several options.

Filing a Formulary Exception

A formulary exception asks the plan to cover a non-formulary drug at a lower cost-sharing tier. To succeed, the prescriber must submit clinical documentation showing that the preferred alternatives (Semglee, Basaglar) are clinically inappropriate for this specific patient. Valid grounds include a documented allergic reaction, persistent injection-site reactions, or a compelling clinical stability argument (the patient has been stable on Lantus for years and switching risks destabilization).

The Step Therapy Override Mechanism

More than 30 states have enacted step therapy ("fail first") override laws that require insurers and Medicaid MCOs to grant overrides within specific timeframes when a patient meets defined clinical criteria. These laws generally allow overrides when the preferred drug is contraindicated, when the patient previously tried and failed the preferred drug, or when the required step therapy would cause clinically significant delay in needed treatment. The National Alliance of Mental Illness (NAMI) step therapy legislative tracker documents state-by-state laws, though NAMI itself is not a primary medical source. For clinical grounding on insulin step therapy and glycemic risk, the ADA's Standards of Care provide the relevant clinical benchmarks. [1]

External Appeal Rights

All state Medicaid programs must provide an external appeal process under federal law. If the internal appeal is denied, the patient or prescriber can request a review by an independent review organization (IRO). IRO decisions are typically binding on the plan. Request the external appeal in writing within the timeframe specified in the denial letter, which is usually 60 days.

Practical Prescriber Checklist for Lantus Medicaid PAs

Prescribers submitting PA requests for Lantus on a state Medicaid formulary should include the following documentation to maximize approval rates.

• Patient's current HbA1c and most recent fasting glucose log
• History of hypoglycemic episodes, with date, severity, and blood glucose values
• Documentation of any trial of the preferred biosimilar, including dates and outcome
• Rationale for brand-specific therapy (device preference is not sufficient in most states; clinical reasoning is required)
• ICD-10 diagnosis codes (E10 series for Type 1, E11 series for Type 2)
• Prescriber NPI and DEA numbers, and state Medicaid provider ID

A complete PA submission at first contact reduces average PA cycle time from a median of 5 business days to 2 business days based on internal HealthRX prescriber advisory data. Incomplete submissions are the single most common reason for first-pass denials in commercial and Medicaid PA workflows.